MiRNAs in PAH: Biomarker, therapeutic target or both?

Drug Discovery Today

Volumn 19, Issue 8, 2014, Pages 1264-1269

  Meloche, Jolyane ^a   Pflieger, Aude ^a   Vaillancourt, Mylène ^a   Graydon, Colin ^a   Provencher, Steeve ^a   Bonnet, Sébastien ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

GENE TARGETING; GENETIC MARKER; HUMAN; NONHUMAN; PATHOGENESIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; HYPERTENSION, PULMONARY; MICRORNAS;

EID: 84906310413     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2014.05.015     Document Type: Review

References (44)

1. K.K. Farh et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution Science 310 2005 1817 1821
2. E. van Rooij, and E.N. Olson MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets J. Clin. Invest. 117 2007 2369 2376
3. A. Krek et al. Combinatorial microRNA target predictions Nat. Genet. 37 2005 495 500
4. E.J. Jung et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients Cancer 118 2012 2603 2614
5. M.J. Wang et al. Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer Int. J. Colorectal Dis. 28 2013 183 189
6. D. Montani et al. Pulmonary arterial hypertension Orphanet. J. Rare Dis. 8 2013 97
7. N. Galie et al. Updated treatment algorithm of pulmonary arterial hypertension J. Am. Coll. Cardiol. 62 25 Suppl. 2013 D60 D72
8. L.R. Frumkin The pharmacological treatment of pulmonary arterial hypertension Pharmacol. Rev. 64 2012 583 620
9. D.B. Badesch et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry Chest 137 2009 376 387
10. N.F. Voelkel et al. Primary pulmonary hypertension between inflammation and cancer Chest 114 3 Suppl. 1998 225S 230S
11. R. Paulin et al. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension J. Mol. Med. 89 2011 1089 1101
12. J. Meloche et al. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension Curr. Vasc. Pharmacol. 2013 Epub ahead of print
13. P. Caruso et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline Arterioscler. Thromb. Vasc. Biol. 30 2010 716 723
14. J.I. Drake et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension Am. J. Respir. Cell. Mol. Biol. 45 2011 1239 1247
15. R.A. McDonald et al. MicroRNA and vascular remodelling in acute vascular injury and pulmonary vascular remodelling Cardiovasc. Res. 93 2012 594 604
16. M. Barrier et al. Today's and tomorrow's imaging and circulating biomarkers for pulmonary arterial hypertension Cell. Mol. Life Sci. 69 2012 2805 2831
17. B.N. Davis-Dusenbery et al. Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation Arterioscler. Thromb. Vasc. Biol. 31 2011 2370 2377
18. J.S. McDonald et al. Analysis of circulating microRNA: preanalytical and analytical challenges Clin. Chem. 57 2011 833 840
19. C. Wei et al. Circulating miRNAs as potential marker for pulmonary hypertension PLoS ONE 8 2013 e64396
20. K. Kang et al. MicroRNA-124 suppresses the transactivation of nuclear factor of activated T cells by targeting multiple genes and inhibits the proliferation of pulmonary artery smooth muscle cells J. Biol. Chem. 288 2013 25414 25427
21. A. Courboulin et al. Role for miR-204 in human pulmonary arterial hypertension J. Exp. Med. 208 2011 535 548
22. S. Jalali et al. Mir-206 regulates pulmonary artery smooth muscle cell proliferation and differentiation PLoS ONE 7 2012 e46808
23. J. Meloche et al. Role for DNA damage signaling in pulmonary arterial hypertension Circulation 129 2013 786 797
24. S. Li et al. MicroRNA-138 plays a role in hypoxic pulmonary vascular remodelling by targeting Mst1 Biochem. J. 452 2013 281 291
25. P. Caruso et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples Circ. Res. 111 2012 290 300
26. D. Gou et al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia Am. J. Physiol. Lung Cell. Mol. Physiol. 303 2012 L682 L691
27. R. Qi et al. Identification of endogenous normalizers for serum microRNAs by microarray profiling: U6 small nuclear RNA is not a reliable normalizer Hepatology 55 2012 1640 1642 author reply 1642-1643
28. T.K. Chung et al. Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1 Int. J. Cancer 130 2012 1036 1045
29. N. Nohata et al. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers Oncotarget 3 2012 9 21
30. V. Olive et al. mir-17-92: a polycistronic oncomir with pleiotropic functions Immunol. Rev. 253 2013 158 166
31. H. Cai et al. Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma Med. Oncol. 30 2013 499
32. L.S. Danielson et al. Cardiovascular dysregulation of miR-17-92 causes a lethal hypertrophic cardiomyopathy and arrhythmogenesis FASEB J. 27 2013 1460 1467
33. Q. Zhang et al. Elevated circulating microRNA-210 levels in patients with hereditary hemorrhagic telangiectasia and pulmonary arteriovenous malformations: a potential new biomarker Biomarkers 18 2013 23 29
34. K. Endo et al. MicroRNA 210 as a biomarker for congestive heart failure Biol. Pharm. Bull. 36 2013 48 54
35. A.G. Bader et al. The promise of microRNA replacement therapy Cancer Res. 70 2010 7027 7030
36. J. Kim et al. An endothelial apelin-FGF link mediated by miR-424 and miR-503 is disrupted in pulmonary arterial hypertension Nat. Med. 19 2013 74 82
37. A. Esquela-Kerscher et al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer Cell Cycle 7 2008 759 764
38. S.S. Pullamsetti et al. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension Am. J. Respir. Crit. Care Med. 185 2012 409 419
39. A. Bouchie First microRNA mimic enters clinic Nat. Biotechnol. 31 2013 577
40. H.L. Janssen et al. Treatment of HCV infection by targeting microRNA N. Engl. J. Med. 368 2013 1685 1694
41. V.V. McLaughlin et al. End points and clinical trial design in pulmonary arterial hypertension J. Am. Coll. Cardiol. 54 1 Suppl. 2009 S97 S107
42. J.S. Fritz et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension Chest 143 2013 315 323
43. G. Savarese et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials J. Am. Coll. Cardiol. 60 2012 1192 1201
44. N.B. Gabler et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials Circulation 126 2012 349 356